Literature DB >> 8690751

Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells.

N Bar-Eli1, H Giloh, M Schlesinger, Z Zakay-Rones.   

Abstract

Susceptibility of lymphoma cells (Daudi, HD-Mar) to Newcastle disease virus toxicity was found to be higher than that of lymphoblastoid cells (Milstein) and of resting peripheral blood lymphocyte (PBL). Phytohemagglutinin- and/or pokeweed-mitogen-activated PBL however, exhibited, elevated sensitivity, similar to that of lymphoma cells. The level of cytotoxicity was monitored by cell viability, inhibition of DNA synthesis and release of 51Cr. When Daudi cells were mixed with PBL they were significantly more sensitive to the killing effect of the virus (70% mortality compared to 30% 30 h after infection, P < 0.05). The degree of sensitivity to viral cytotoxicity was unrelated to the efficacy of adsorption, which was similar for all cell lines as shown by immunofluorescent staining and flow cytometry. Also an influenza strain A/PR/8/34 (H1N1) adsorbed but did not affect the viability of any of the cells tested. Our results demonstrate that New-castle disease virus caused preferential damage to lymphoma cells as compared to non-cancerous normal cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690751     DOI: 10.1007/bf01212880

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  30 in total

1.  EFFECT OF ACTIVE AND ULTRAVIOLET-IRRADIATED INACTIVE VACCINIA VIRUS ON THE DEVELOPMENT OF SHAY LEUKEMIA IN RATS.

Authors:  Z ZAKAY-RONESS; H BERNKOPF
Journal:  Cancer Res       Date:  1964-04       Impact factor: 12.701

2.  Killing of Burkitt-lymphoma-derived Daudi cells by ultraviolet-inactivated vaccinia virus.

Authors:  L Grunwald-Beard; H Gamliel; G Parag; S Vedantham; Z Zakay-Rones
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.

Authors:  H Schild; P von Hoegen; V Schirrmacher
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Lymphocyte receptors for myxoviruses and paramyxoviruses.

Authors:  J F Woodruff; J J Woodruff
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

5.  Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus.

Authors:  A P Lieberman; P M Pitha; H S Shin; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

6.  Sensitivity of Burkitt lymphoma Daudi cells to inactive influenza virus.

Authors:  Y Shlomi; Z Zakay-Rones
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

7.  Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity.

Authors:  R M Lorence; P A Rood; K W Kelley
Journal:  J Natl Cancer Inst       Date:  1988-10-19       Impact factor: 13.506

8.  Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy.

Authors:  R M Lorence; B B Katubig; K W Reichard; H M Reyes; A Phuangsab; M D Sassetti; R J Walter; M E Peeples
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

9.  Characterization of a novel cell-surface molecule expressed on subpopulations of activated T and B cells.

Authors:  G Laszlo; K S Hathcock; H B Dickler; R J Hodes
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

10.  Measles infection of human mononuclear cells. I. Acute infection of peripheral blood lymphocytes and monocytes.

Authors:  J L Sullivan; D W Barry; S J Lucas; P Albrecht
Journal:  J Exp Med       Date:  1975-09-01       Impact factor: 14.307

View more
  13 in total

Review 1.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

2.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

Review 3.  Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.

Authors:  Sonia Tusell Wennier; Jia Liu; Grant McFadden
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

Review 4.  Cancer stem cells: the final frontier for glioma virotherapy.

Authors:  Mahua Dey; Ilya V Ulasov; Matthew A Tyler; Adam M Sonabend; Maciej S Lesniak
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

Review 5.  Virotherapy against malignant glioma stem cells.

Authors:  Mahua Dey; Ilya V Ulasov; Maciej S Lesniak
Journal:  Cancer Lett       Date:  2009-07-29       Impact factor: 8.679

Review 6.  Oncolytic viruses.

Authors:  J Nemunaitis
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.651

7.  Differential microRNA Expression in Newcastle Disease Virus-Infected HeLa Cells and Its Role in Regulating Virus Replication.

Authors:  Yu Chen; Shanshan Zhu; Yuru Pei; Jiao Hu; Zenglei Hu; Xiaowen Liu; Xiaoquan Wang; Min Gu; Shunlin Hu; Xiufan Liu
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

8.  Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma.

Authors:  Diana Sánchez; Rosana Pelayo; Luis Alberto Medina; Eduardo Vadillo; Rogelio Sánchez; Luis Núñez; Gabriela Cesarman-Maus; Rosa Elena Sarmiento-Silva
Journal:  Viruses       Date:  2015-12-23       Impact factor: 5.048

9.  Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy.

Authors:  Ahmed Majeed Al-Shammari; Huda Rameez; Maha F Al-Taee
Journal:  Oncolytic Virother       Date:  2016-04-20

Review 10.  Therapeutic potential of oncolytic Newcastle disease virus: a critical review.

Authors:  Shay Tayeb; Zichria Zakay-Rones; Amos Panet
Journal:  Oncolytic Virother       Date:  2015-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.